Edesa Biotech's Paridiprubart Shows Promise in Inhibiting Inflammation from Influenza and Other Pathogens

Edesa Biotech, Inc. announced positive findings from an in vitro study of its monoclonal antibody candidate, paridiprubart, against a panel of respiratory pathogens. The study demonstrated that inflammation signaling from multiple pathogens, including Influenza A, coronavirus, and a common bacterium (H. influenzae), was inhibited by Edesa's TLR4 antagonist, paridiprubart. These findings support ..